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Randomized Trials or Population-based RegistriesNew methods introduced for treatment or prophy-
laxis have to be better, safer, simpler and/or cheaper
than the old ones. The new method could derive
from pharmacological research, invention of new
techniques or observations from registries. Today it
is rarely a question of dramatic or all-or-none effects.
Therefore, properly designed studies must be per-
formed to show differences in effect. The classical
method is the randomized controlled trial (RCT), but
data can also be derived from observational studies or
registries, both types of studies having, strengths and
weaknesses. The researcher and clinician must be
familiar with those aspects and possible flaws in
design and analysis.
The clinical problems are how to draw the proper
conclusions from RCTs, how to transfer results into
the relevant clinical setting and how to analyze
whether the outcome in real life is similar to that of
the RCTs. Treatment indications are likely to be
broader and exclusion criteria likely to be less strict.
An RCT should only be performed if there is a true
uncertainty about the value of one treatment versus
another.1 This is also an ethical prerequisite with the
aim to increase knowledge for better care of patients.
The benefit and disadvantage of a treatment must be
balanced.
An RCT is truly experimental with random alloca-
tion of the participants to exposure. In most studies
only one factor is varied. Correctly performed, the
RCT has a high internal validity. This is a safe way
to compare treatments and avoid as far as possible
the influences of selection bias and various con-
founders. The background and prognostic factors
are kept balanced. The control group allows us to as-
sess possible causal associations, especially when the
causal chain between intervention and outcome is
short. The patient material is homogenous and well
defined and the procedures, treatments and outcome
measurements are well controlled. It is almost always
possible to identify and randomize patients in a grey
area of uncertainty.2 The criteria set up by authorities
such as Food and Drug Administration (FDA) and
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pharmacological studies.
The strictly defined RCT situation may differ from
clinical reality, resulting in poor external validity
and generalizability. The clinicians must ask how
applicable the results are to patients in their practice.
Selection mechanisms and criteria for inclusion and
exclusion may make the inclusion rate very slow
and prolong the study period, casting doubt on the
clinical relevance of the study results. A logbook of
consecutive patients with reasons for exclusion is im-
portant. The flow of patients and selection mecha-
nisms must be transparent.
RCTs rarely take into consideration changes over
time, which could be due to factors outside the study
situation, and sometimes the results may be obsolete,
when the study is finalized. This is especially true in
studies on new devices with rapid technical develop-
ment. Surrogate endpoints are often used, the clinical
relevance of which are dubious. A surrogate must cor-
relate with clinical outcome as well as with the effect
of the intervention.3 When the outcome event is rare,
multicentre trials may be a solution. Inclusion of low
risk patients dilutes the frequency of end points. The
tendency not to publish small trials is serious, because
they will fall outside systematic reviews and meta-
analyses, which may distort the conclusions. RCTs
are expensive. Financial support from the industry
may influence the results in an industry-positive
way, even when the studies are blind. The majority
of RCTs are designed to study effect and rarely to
study infrequent side effects, adverse events and com-
plications. Sometimes this may not even be possible
because the complications are not known beforehand
or very rare. Most RCTs are dimensioned to study
short term effects, whereas many patient groups
have chronic diseases, atherosclerosis being one ex-
ample. Many problems are difficult to study with
a blind design, such as technical innovations, surgical
techniques, etc. This increases a danger of bias, and
blinded outcome assessment should be used.4,5 In-
stead of being transparent the reporting of RCTs
may be incomplete and inaccurate. The CONSORTn behalf of European Society for Vascular Surgery.
254 Editorialstatement (CONsolidated Standards Of Reporting Tri-
als) has introduced a checklist and flow diagram of es-
sential items to be included when reporting RCTs.6e8
The results of an RCT are less likely to be generaliz-
able if the outcome of the intervention is highly de-
pendent on the provider or the clinical setting such
as in surgery, as compared to drug treatment.
Various types of registries exist, including those
administered by industry to monitor performance of
new devices or drugs. In population-based registries
with a large number of individuals, the impact of
a new therapy can be evaluated. Dynamics over
time can be followed as well as the influence of devel-
oping technologies and long-term effects. Registry
studies give the opportunity to analyze the external
validity of RCTs and can generate hypotheses. It is
possible to identify risk factors, prognostic factors
etc., which are important to handle in the design of
RCT trials. Case-control studies are particularly effec-
tive, when rare events are to be studied, since those
events have already occurred when the study is initi-
ated. If a case-control is performed nested in the
cohort of a registry, risk factors are recorded prospec-
tively in the registry. Thus, the major weakness of
case-control studies are dealt with. Survival analysis
can be undertaken, linkage being made to population
registries.
The design, however, is not experimental and data
on exposure to a specific treatment or action may be
uncertain. The patient material is heterogeneous and
sometimes difficult to control for confounding factors.
The effect of confounders does not diminish with in-
creasing size of the study. Moreover, it is only possible
to control confounders that are known. Factors of im-
portance may change over time. There is an obvious
risk for selection bias. One criticism is the sometimes
small impact on patient care because of poor feedback
to the profession and inertia in the system. The orga-
nizers of a registry must guarantee a dynamic feed-
back to the users. Underreporting in registries can
be a problem. Non-registered patients often have
a worse outcome, underlining the importance to
maintain a high registration rate. Registry data may
be misused to introduce new treatment or products
without relevant RCTs. This is not possible with phar-
macological products and should not be concerning
technical devices.
Over the years, there have been several examples of
results from registries or observational studies leading
to rather firm conclusions about treatments, which
have not been able to confirm in RCTs. One example
is the lower risk of coronary events and progression
of coronary lesions with vitamin E intake as suggested
in population-based studies.9e11 This effect was
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lysis on 52 000 patients (HOPE).
After RCTs and systematic reviews showing a bene-
ficial effect of ß-blockers in elderly patients undergoing
surgery,13e15 a population based cohort study showed
one ß-blocker (atenolol) to be superior to another
(metoprolol) in reducing myocardial infarction and
death.16 An RCT directly comparing these two
ß-blockers in unlikely to be performed.
In vascular surgery the technique of endovascular
aneurysm repair (EVAR) is a contemporary example
how the medical profession sometimes is slow
and inefficient in assessing new treatments. Since
the technique was described, several minor studies
reported promising results. The EUROSTAR volun-
tary register was launched 1996 to record outcome
of patients treated with EVAR. Reports indicated
that the median aneurysm diameter was 5.7 cm
meaning that around half of the registered patients
had an aneurysm size that would not merit opera-
tion according to common standards. With such
a skewed selection of patients generalizibility of
findings could be questioned. There is a similar
UK based registry, RETA, also from 1996, five years
results recently reported.17 Not until fifteen years
after the introduction of EVAR results of major
RCTs were published.18e20
When results of RCTs are made public, the poten-
tial impact outside the study situation must be evalu-
ated. An example is what happened with carotid
endarterectomy in Sweden when the results from
the Asymptomatic Carotid Surgery Trial (ACST)
were made public. After the first report, the number
of carotid endarterectomies for asymptomatic disease
started to increase and the increase has continued.
The results in the Swedish Vascular Registry concern-
ing postoperative mortality and permanent neuro-
logical morbidity are not inferior to the results in the
RCTs, which is reassuring.21
Both economic and patient resources must be opti-
mally used to give clinical useful information. The
size of the effect is often obtained in the RCTs, but
questions on how representative and relevant out-
come are equally important.
RCTs and registry studies are both needed and are
complementary (Fig. 1). Their respective advantages
and disadvantages must be known both by those de-
signing the studies, by those analyzing the data, and
by those reading about the results. The scientific
problem must be clearly defined and the optimal
study and statistical methodology used. Registries
can complement data from RCTs to analyze treat-
ment effect and rare side effects on a population
basis.
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ings to best medical practice is difficult.22 A popula-
tion-based registry may be helpful in analysing the
ways in which this implementation is successful or
not. When results from RCTs are compared with those
from population-based registry studies it is important
to analyze differences in background factors which
could offer explanations of differences in outcome.
One model which has been shown to work reasonably
well in vascular surgery, when national results are
compared, is to apply the POSSUM physiology score
as shown by the Audit and Research Committee of
the Vascular Surgical Society of Great Britain and
Ireland.23
Conclusion
With well defined scientific questions in combina-
tion with adequate design and analysis as well as
awareness of strengths and weaknesses, both RCTs
and population based registry studies do give sig-
nificant information. Both designs require external
and internal validation assuring that patients not
randomized, or not registered, do not introduce
bias. Finally, it is not a question of either/or e we
need both.
References
1 FREEDMAN B. Equipoise and the ethics of clinical research. N Engl
J Med 1987;317(3):141e145.
2 PETO R, BAIGENT C. Trials: the next 50 years. Large scale rando-
mised evidence of moderate benefits. BMJ 1998;317(7167):
1170e1171.
3 FLEMING TR, DEMETS DL. Surrogate end points in clinical trials:
are we being misled? Ann Intern Med 1996;125(7):605e613.
4 ROSEN M. On randomized controlled trials and lifestyle interven-
tions. Int J Epidemiol 1989;18(4):993e994.
Registries
RCTs
Registries
Feasibility, training
& safety
Clinical efficacy & cost-
effectiveness
Long-term outcomes, new 
developments & generalisability
Fig. 1. ‘‘Tracker’’ design for new technologies.5 LINDHOLM L, ROSEN M. What is the ‘‘golden standard’’ for assess-
ing population-based interventions?eproblems of dilution bias.
J Epidemiol Community Health 2000;54(8):617e622.
6 BEGG C, CHO M, EASTWOOD S, HORTON R, MOHER D, OLKIN I
et al. Improving the quality of reporting of randomized
controlled trials. The CONSORT statement. JAMA 1996;276(8):
637e639.
7 MOHER D, SCHULZ KF, ALTMAN DG. The CONSORT statement: re-
vised recommendations for improving the quality of reports of
parallel-group randomised trials. Lancet 2001;357(9263):1191e
1194.
8 EGGER M, JUNI P, BARTLETT C. Value of flow diagrams in re-
ports of randomized controlled trials. JAMA 2001;285(15):
1996e1999.
9 RIMM EB, STAMPFER MJ, ASCHERIO A, GIOVANNUCCI E, COLDITZ GA,
WILLETT WC. Vitamin E consumption and the risk of
coronary heart disease in men. N Engl J Med 1993;328(20):
1450e1456.
10 STAMPFER MJ, HENNEKENS CH, MANSON JE, COLDITZ GA,
ROSNER B, WILLETT WC. Vitamin E consumption and the risk
of coronary disease in women. N Engl J Med 1993;328(20):
1444e1449.
11 HODIS HN, MACK WJ, LABREE L, CASHIN-HEMPHILL L, SEVANIAN A,
JOHNSON R et al. Serial coronary angiographic evidence that anti-
oxidant vitamin intake reduces progression of coronary artery
atherosclerosis. JAMA 1995;273(23):1849e1854.
12 YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G. Effects
of an angiotensin-converting-enzyme inhibitor, ramipril, on car-
diovascular events in high-risk patients. The Heart Outcomes
Prevention Evaluation Study Investigators. N Engl J Med 2000;
342(3):145e153.
13 STEVENS RD, BURRI H, TRAMER MR. Pharmacologic myocardial
protection in patients undergoing noncardiac surgery: a quantita-
tive systematic review. Anesth Analg 2003;97(3):623e633.
14 AUERBACH AD, GOLDMAN L. beta-Blockers and reduction of
cardiac events in noncardiac surgery: scientific review. JAMA
2002;287(11):1435e1444.
15 POLDERMANS D, BOERSMA E, BAX JJ, THOMSON IR, VAN DE VEN LL,
BLANKENSTEIJN JD et al. The effect of bisoprolol on periopera-
tive mortality and myocardial infarction in high-risk patients
undergoing vascular surgery. Dutch Echocardiographic Car-
diac Risk Evaluation Applying Stress Echocardiography Study
Group. N Engl J Med 1999;341(24):1789e1794.
16 REDELMEIER D, SCALES D, KOPP A. Beta blockers for elective sur-
gery in elderly patients: population based, retrospective cohort
study. BMJ 2005;331(7522):932.
17 THOMAS SM, BEARD JD, IRELAND M, AYERS S. Results from the pro-
spective registry of endovascular treatment of abdominal aortic
aneurysms (RETA): mid term results to five years. Eur J Vasc
Endovasc Surg 2005;29(6):563e570.
18 GREENHALGH RM, BROWN LC, KWONG GP, POWELL JT, THOMPSON SG.
Comparison of endovascular aneurysm repair with open repair
in patients with abdominal aortic aneurysm (EVAR trial 1),
30-day operative mortality results: randomised controlled trial.
Lancet 2004;364(9437):843e848.
19 Endovascular aneurysm repair versus open repair in patients
with abdominal aortic aneurysm (EVAR trial 1): randomised
controlled trial. Lancet 2005;365(9478):2179e2186.
20 PRINSSEN M, VERHOEVEN EL, BUTH J, CUYPERS TWM, VAN
SAMBEEK MRHM, BALM R et al. A randomized trial comparing
conventional and endovascular repair of abdominal aortic
aneurysms. N Engl J Med 2004;351(16):1607e1618.
21 KRAGSTERMAN B, PA¨RSSON H, BERGQVIST D, BJO¨RCK M. Outcomes of
carotid endarterectomy for asymptomatic stenosis in Sweden are
improvingeresults from a population based registry. J Vasc Surg
2006;44:79e85.
22 GROL R, GRIMSHAW J. From best evidence to best practice: effective
implementation of change in patients’ care. Lancet 2003;
362(9391):1225e1230.
23 PRYTHERCH DR, RIDLER BM, BEARD JD, EARNSHAW JJ. Audit and
Research Committee. The Vascular Society of Great Britain and
Eur J Vasc Endovasc Surg Vol 34, September 2007
256 EditorialIreland. A model for national outcome audit in vascular surgery.
Eur J Vasc Endovasc Surg 2001;21(6):477e483.
D. Bergqvist1*, M. Bjo¨rck1, J. Sa¨we2, T. Troe¨ng3
1Department of Surgical Sciences, Section of Vascular
Surgery, Uppsala University Hospital, Sweden A2SBU The Swedish Council on Technology Assessment
in Health Care, Stockholm, Sweden
3Department of Surgery, Blekingesjukhuset,
Karlskrona, Sweden
ccepted 28 June 2007*Corresponding author. D. Bergqvist MD, PhD, FRCS, Professor of
Vascular Surgery, Department of Surgical Sciences, Section of
Vascular Surgery, Uppsala University Hospital, SE 751 85 Uppsala,
Sweden.
E-mail address: david.bergqvist@surgsci.uu.se
Eur J Vasc Endovasc Surg Vol 34, September 2007
